All In Biotech

Free tool

FAERS Monitor: Cytalux

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214907 or its brand name (Cytalux, Pafolacianine Sodium). Reports on generic versions are filed under their own applications.

Reports

63

Serious

13

21% of reports

Hospitalization

8

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea35
  • vomiting20
  • pruritus7
  • dyspnoea6
  • chest discomfort5
  • drug effect less than expected4
  • flushing4
  • wheezing4
  • false positive investigation result3
  • hyperhidrosis3
  • abdominal pain2
  • chest pain2
  • death2
  • dizziness2
  • heart rate increased2

Reports by year received

View as table
YearReports
20232
202424
202519
202618

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,096 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
false positive investigation resultSignal3995.6329.42,063
drug effect less than expectedSignal490.134.9269
wheezingSignal422.58.762
chest discomfortSignal516.37.058
nauseaSignal3514.811.8452
vomitingSignal2014.29.9238
flushingSignal413.15.134
hyperhidrosisSignal37.82.612
heart rate increased26.71.75
pruritusSignal76.13.025
chest pain23.60.92
dyspnoeaSignal63.51.79
abdominal pain22.90.71
dizziness21.30.30
death20.80.20

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.